The U.S. life science construction market is pivoting from speculative lab space to infrastructure-heavy, owner-driven biomanufacturing and research projects amid high vacancy rates.
The U.S. life science development sector is undergoing a structural recalibration as vacancy rates across major hubs climbed from approximately 7% in 2021 to 30% by the first quarter of 2026. Following an unprecedented surge of 60 million square feet of lab space delivered between 2020 and 2025, developers are pulling back on speculative projects due to tighter capital conditions and slowing demand. Firms are increasingly shifting their focus toward core assets or specialized, owner-driven biomanufacturing facilities.
Industry experts note a growing trend toward large-scale projects exceeding $1 billion that prioritize complex utility systems, clean-room infrastructure, and process piping over traditional research environments. Notable examples of this transition include Genentech’s $2 billion expansion in Holly Springs, North Carolina, and Procter & Gamble’s $1 billion Gillette research headquarters in Boston, which features a 335,000-square-foot lab facility. Contractors, including DPR Construction and CRB, report that while speculative development has largely paused, institutional investment in pharmaceutical manufacturing and R&D infrastructure remains a strategic priority.
Daily emails covering the projects and news that match your service area, building types, and the project stages you bid on.
Free now — first 50 founding members lock in 30% off at launch.
Free. One click to unsubscribe. No tracking pixels.